Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"

  • STATUS
    Recruiting
  • participants needed
    1968
  • sponsor
    Cardresearch
Send
Updated on 16 February 2024
See if I qualify
critical illness
pulmonary disease
corticosteroids
renal disease
dialysis
cardiovascular disease
heart disease
hypertension
coronary artery disease
immunosuppression
prednisone
chronic disease
cough
steroid therapy
corticosteroid therapy
covid-19
SARS
ritonavir
hydroxychloroquine
critically ill
lung disease
chronic lung disease
respiratory symptom
lopinavir
lopinavir/ritonavir
cardiovascular diseases
lopinavir / ritonavir
ritonavir oral tablet
acute respiratory syndrome (sars)
lopinavir/ ritonavir
diabetes
insulin

Summary

The COVID-19 pandemic has been characterized by high morbidity and mortality, especially in certain subgroups of patients. To date, no treatment has been shown to be effective in controlling this disease in hospitalized patients with moderate and / or severe cases of this disease. Hydroxychloroquine and lopinavir / ritonavir have been shown to inhibit SARS-CoV viral replication in experimental severe acute respiratory symptoms models and have similar activity against SARS-CoV2. Although widely used in studies of critically ill patients, to date, no study has demonstrated its role on the treatment of high-risk, newly diagnosed patients with COVID-19 and mild symptoms.

Description

In December 2019 a series of viral pneumonia cases were reported in the city of Wuhan, China. A new subtype of coronavirus has been identified as the causative agent of this condition. On February 11, 43,103 cases had already been described and on this day the World Health Organization (WHO) named this disease as COVID-19. With. The disease had spread out to several countries on different continents and on March 11, WHO declared a state of worldwide pandemic. Today (April 25, 2020) there are 2,719,897 cases and 187,705 deaths documented, with a global case-fatality ratio of 6.9%.

To date, no treatment has been identified as effective in combating this disease which has been identified as with high mortality, therefore there are no specific therapeutic options. So far, efforts have been focused on the treatment of patients hospitalized with dyspnea and, although several promising drugs are being evaluated, none has demonstrated effectiveness in reducing morbidity and mortality at this stage of the disease, suggesting that perhaps the best time to use medications either before the onset of severe symptoms of respiratory distress.

Thus, we propose the use of two drugs which experimentally have shown activity against SARS-CoV2 and being used in severely ill patients with COVID-19. Our hypothesis is that perhaps using such drugs before onset of complications will allow better outcomes on this patient population.

Details
Condition Coronavirus Infection, Viral infection, Severe Acute Respiratory Syndrome, Acute Respiratory Infection, Covid 19
Age 18years - 100years
Treatment Placebo, Hydroxychloroquine Sulfate Tablets, Lopinavir/ Ritonavir Oral Tablet, Hydroxychloroquine Sulfate Tablets plus Lopinavir/ Ritonavir Oral Tablets
Clinical Study IdentifierNCT04403100
SponsorCardresearch
Last Modified on16 February 2024

Eligibility

 Yes No Not Sure

Inclusion Criteria

Patients with RT-PCR diagnosis of COVID-19 or a clinical condition compatible
with COVID-19 and respiratory symptoms, presenting
Persistent dry cough associated with axillary temperature > 37.7 Celsius
OR
B. Recent onset of Flu-like Respiratory Symptoms associated with dry cough
OR
C. Tomographic image compatible with COVID 19 infection
\. Men and women aged > 50 years OR: Patients over 18 years of age with at
least one of the following criteria
Diabetes requiring oral medication or insulin
Arterial hypertension requiring at least 01 oral medication for treatment
Known cardiovascular diseases (CHF of any etiology, documented Coronary Artery Disease, Clinically overt heart disease)
Symptomatic chronic lung disease and/ or medically controlled
Patients with a history of transplantation
Patient with stage IV chronic kidney disease or on dialysis
Patients on current Immunosuppression and/or using corticosteroid therapy (equivalent to at least 10 mg of oral prednisone per day)
Willingness to comply with study related procedures 3\. Ability to provide informed consent before any protocol-related procedures

Exclusion Criteria

RT-PCR exam for COVID-19 negative during the screening visit
Patients with an acute respiratory condition compatible with COVID-19 being hospitalized
Patients with an acute respiratory condition and with moderate to high probability of not being a COVID infection 19
Dyspnea secondary to other acute and chronic respiratory causes or infections (eg, decompensated Chronic Obstructive Pulmonary Disease, acute bronchitis, pneumonia, primary pulmonary arterial hypertension)
Severe respiratory clinical condition, presenting at least ONE of the criteria below
Respiratory Rate> 28 / min
Arterial Oxygen Saturation < 92% with nasal oxygen therapy at 10 l/ min
PaO2 / FIO2 <300 mmHg
History of Cardiac Arrhythmia or Long QT Syndrome; 5. Use of Medications that are known to prolong QTc: Citalopram, Venlafaxine, Bupropion and with no possibility of suspension during the period of investigational medical product administration. 6. Inability to take oral medications; 7. Patients on continuous use of Amiodarone and / or PGE5 Inhibitors (Ex .: Sildenafil and similar). 8. Use of Digoxin, Cyclosporine, Cimetidine, Tamoxifen. 9. Use of anticonvulsants, antifungals, immunosuppressants other than corticotherapy. 10. Use of Hydroxychloroquine for other indications 11. Use of chemoprophylaxis for malaria. 12. Psoriasis in a form other than cutaneous 13. Porphyria 14. Use of protease inhibitors, ritonavir or Cobicistat 15. Clinical history of Liver Cirrhosis or Child-Pugh C classification; 16. Patients with a history of degenerative retinal diseases (patients with retinal diseases due to diabetes and hypertension can participate in the research); 17. Patient with a clinically relevant history of hearing loss; 18. Patients with known severe degenerative neurological diseases and / or severe mental illness; 19. Inability of the patient or representative to give consent or adhere to the procedures proposed in the protocol; 20. Known hypersensitivity and / or intolerance to Hydroxychloroquine. 21. Hypersensitivity and / or intolerance Lopinavir / Ritonavir
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
Message sent successfully.
We have submitted the information you provided to the research team at the location you chose. For your records, we have sent a copy of the message to your email address.
If you would like to be informed of other studies that may be of interest to you, you may sign up for Patient Notification Service.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Other language

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

critical illness
pulmonary disease
corticosteroids
renal disease
dialysis
cardiovascular disease
heart disease
hypertension
coronary artery disease
immunosuppression
prednisone
chronic disease
cough
steroid therapy
corticosteroid therapy
covid-19
SARS
ritonavir
hydroxychloroquine
critically ill
lung disease
chronic lung disease
respiratory symptom
lopinavir
lopinavir/ritonavir
cardiovascular diseases
lopinavir / ritonavir
ritonavir oral tablet
acute respiratory syndrome (sars)
lopinavir/ ritonavir
diabetes
insulin

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.